{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T03:01:23Z","timestamp":1763348483467,"version":"build-2065373602"},"reference-count":48,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Center of Molecular Immunology, Havana, Cuba"},{"DOI":"10.13039\/100001320","name":"Roswell Park Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,8,16]]},"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Immune suppression is common in neoplasia and a major driver is tumor-induced myeloid dysfunction. Yet, overcoming such myeloid cell defects remains an untapped strategy to reverse suppression and improve host defense. Exposure of bone marrow progenitors to heightened levels of myeloid growth factors in cancer or following certain systemic treatments promote abnormal myelopoiesis characterized by the production of myeloid-derived suppressor cells (MDSCs) and a deficiency in antigen-presenting cell function. We previously showed that a novel immune modulator, termed \u2018very small size particle\u2019 (VSSP), attenuates MDSC function in tumor-bearing mice, which was accompanied by an increase in dendritic cells (DCs) suggesting that VSSP exhibits myeloid differentiating properties. Therefore, here, we addressed two unresolved aspects of the mechanism of action of this unique immunomodulatory agent: (1) does VSSP alter myelopoiesis in the bone marrow to redirect MDSC differentiation toward a monocyte\/macrophage or DC fate? and (2) does VSSP mitigate the frequency and suppressive function of human tumor-induced MDSCs?<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>To address the first question, we first used a murine model of granulocyte-colony stimulating factor-driven emergency myelopoiesis following chemotherapy-induced myeloablation, which skews myeloid output toward MDSCs, especially the polymorphonuclear (PMN)-MDSC subset. Following VSSP treatment, progenitors and their myeloid progeny were analyzed by immunophenotyping and MDSC function was evaluated by suppression assays. To strengthen rigor, we validated our findings in tumor-bearing mouse models. To address the second question, we conducted a clinical trial in patients with metastatic renal cell carcinoma, wherein 15 patients were treated with VSSP. Endpoints in this study included safety and impact on PMN-MDSC frequency and function.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We demonstrated that VSSP diminished PMN-MDSCs by shunting granulocyte-monocyte progenitor differentiation toward monocytes\/macrophages and DCs with heightened expression of the myeloid-dependent transcription factors interferon regulatory factor-8 and PU.1. This skewing was at the expense of expansion of granulocytic progenitors and rendered the remaining MDSCs less suppressive. Importantly, these effects were also demonstrated in a clinical setting wherein VSSP monotherapy significantly reduced circulating PMN-MDSCs, and their suppressive function.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Altogether, these data revealed VSSP as a novel regulator of myeloid biology that mitigates MDSCs in cancer patients and reinstates a more normal myeloid phenotype that potentially favors immune activation over immune suppression.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2022-004710","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T11:24:19Z","timestamp":1663932259000},"page":"e004710","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Mitigating the prevalence and function of myeloid-derived suppressor cells by redirecting myeloid differentiation using a novel immune modulator"],"prefix":"10.1136","volume":"10","author":[{"given":"Liliana","family":"Oliver","sequence":"first","affiliation":[{"name":"Department of Immunoregulation, Immunology and Immunotherapy Direction, Center of Molecular Immunology, Havana, Cuba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rydell","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Department of Immunoregulation, Immunology and Immunotherapy Direction, Center of Molecular Immunology, Havana, Cuba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Diaz","sequence":"additional","affiliation":[{"name":"Department of Oncology, Joaqu\u00edn Albarr\u00e1n Hospital, Havana, Cuba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anet","family":"Vald\u00e9s","sequence":"additional","affiliation":[{"name":"Department of Immunoregulation, Immunology and Immunotherapy Direction, Center of Molecular Immunology, Havana, Cuba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean H","family":"Colligan","sequence":"additional","affiliation":[{"name":"Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J","family":"Nemeth","sequence":"additional","affiliation":[{"name":"Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA"},{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle Y F","family":"Twum","sequence":"additional","affiliation":[{"name":"Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audry","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Immunoregulation, Immunology and Immunotherapy Direction, Center of Molecular Immunology, Havana, Cuba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Fern\u00e1ndez-Medina","sequence":"additional","affiliation":[{"name":"Department of Immunoregulation, Immunology and Immunotherapy Direction, Center of Molecular Immunology, Havana, Cuba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise M","family":"Carlson","sequence":"additional","affiliation":[{"name":"Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA"},{"name":"Department of Medicine, Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin H","family":"Eng","sequence":"additional","affiliation":[{"name":"Department of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary L","family":"Hensen","sequence":"additional","affiliation":[{"name":"Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maura L","family":"R\u00e1bade-Chediak","sequence":"additional","affiliation":[{"name":"Department of Immunoregulation, Immunology and Immunotherapy Direction, Center of Molecular Immunology, Havana, Cuba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Enrique","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Immunoregulation, Immunology and Immunotherapy Direction, Center of Molecular Immunology, Havana, Cuba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelvin P","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA"},{"name":"Department of Medicine, Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Perez","sequence":"additional","affiliation":[{"name":"Clinical Direction, Center of Molecular Immunology, Havana, Cuba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7703-1425","authenticated-orcid":false,"given":"Jason B","family":"Muhitch","sequence":"additional","affiliation":[{"name":"Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8342-7779","authenticated-orcid":false,"given":"Circe","family":"Mesa","sequence":"additional","affiliation":[{"name":"Department of Immunoregulation, Immunology and Immunotherapy Direction, Center of Molecular Immunology, Havana, Cuba"},{"name":"Innovative Immunotherapy Alliance, S. A. Mariel, Artemisa, Cuba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8742-4708","authenticated-orcid":false,"given":"Scott I","family":"Abrams","sequence":"additional","affiliation":[{"name":"Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"key":"2025100308202000000_10.9.e004710.1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-600833"},{"key":"2025100308202000000_10.9.e004710.2","doi-asserted-by":"publisher","DOI":"10.1126\/science.8016643"},{"key":"2025100308202000000_10.9.e004710.3","doi-asserted-by":"crossref","first-page":"284","DOI":"10.15698\/cst2019.09.197","article-title":"Myelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression","volume":"3","author":"Sica","year":"2019","journal-title":"Cell Stress"},{"key":"2025100308202000000_10.9.e004710.4","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.155"},{"key":"2025100308202000000_10.9.e004710.5","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000201"},{"key":"2025100308202000000_10.9.e004710.6","doi-asserted-by":"publisher","DOI":"10.1038\/nri3175"},{"key":"2025100308202000000_10.9.e004710.7","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3581"},{"key":"2025100308202000000_10.9.e004710.8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601722"},{"key":"2025100308202000000_10.9.e004710.9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.seminoncol.2018.05.001","article-title":"Cancer-Induced systemic myeloid dysfunction: implications for treatment and a novel nanoparticle approach for its correction","volume":"45","author":"Alvarez","year":"2018","journal-title":"Semin Oncol"},{"key":"2025100308202000000_10.9.e004710.10","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001465"},{"key":"2025100308202000000_10.9.e004710.11","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-2-5"},{"key":"2025100308202000000_10.9.e004710.12","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1016\/j.vaccine.2012.02.054","article-title":"Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for antigen-specific cytotoxic T lymphocyte response stimulation under leukopenic conditions","volume":"30","author":"Oliver","year":"2012","journal-title":"Vaccine"},{"key":"2025100308202000000_10.9.e004710.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00219-4"},{"key":"2025100308202000000_10.9.e004710.14","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.1016\/j.vaccine.2005.07.049","article-title":"Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors","volume":"23","author":"Torr\u00e9ns","year":"2005","journal-title":"Vaccine"},{"key":"2025100308202000000_10.9.e004710.15","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22085"},{"key":"2025100308202000000_10.9.e004710.16","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.vaccine.2012.01.006","article-title":"CIGB-247: a VEGF-based therapeutic vaccine that reduces experimental and spontaneous lung metastasis of C57BL\/6 and BALB\/c mouse tumors","volume":"30","author":"Bequet-Romero","year":"2012","journal-title":"Vaccine"},{"key":"2025100308202000000_10.9.e004710.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.11.102"},{"key":"2025100308202000000_10.9.e004710.18","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1016\/j.vaccine.2012.08.020","article-title":"Very small size proteoliposomes (VSSP) and Montanide combination enhance the humoral immuno response in a GnRH based vaccine directed to prostate cancer","volume":"30","author":"Aguilar","year":"2012","journal-title":"Vaccine"},{"key":"2025100308202000000_10.9.e004710.19","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1016\/j.vaccine.2004.02.010","article-title":"Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation","volume":"22","author":"Mesa","year":"2004","journal-title":"Vaccine"},{"key":"2025100308202000000_10.9.e004710.20","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.vaccine.2005.01.114","article-title":"Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for dendritic cell activation","volume":"24 Suppl 2","author":"Mesa","year":"2006","journal-title":"Vaccine"},{"key":"2025100308202000000_10.9.e004710.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2008.03.002"},{"key":"2025100308202000000_10.9.e004710.22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.8823"},{"key":"2025100308202000000_10.9.e004710.23","doi-asserted-by":"publisher","DOI":"10.1172\/JCI68189"},{"key":"2025100308202000000_10.9.e004710.24","first-page":"19","article-title":"Efficacy and safety of ior\u00ae LeukoCIM (G-CSF) in patients with neutropenia after chemotherapy","volume":"45","author":"Perez","year":"2011","journal-title":"Revista Cubana de Farmacia"},{"key":"2025100308202000000_10.9.e004710.25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.1.270"},{"key":"2025100308202000000_10.9.e004710.26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.5.2851"},{"key":"2025100308202000000_10.9.e004710.27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3541"},{"key":"2025100308202000000_10.9.e004710.28","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-06-0628"},{"key":"2025100308202000000_10.9.e004710.29","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M500345200"},{"key":"2025100308202000000_10.9.e004710.30","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.21010"},{"key":"2025100308202000000_10.9.e004710.31","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12469"},{"key":"2025100308202000000_10.9.e004710.32","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2883"},{"key":"2025100308202000000_10.9.e004710.33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1332"},{"key":"2025100308202000000_10.9.e004710.34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2530"},{"key":"2025100308202000000_10.9.e004710.35","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3389\/fcell.2020.00351","article-title":"Friend or foe? recent strategies to target myeloid cells in cancer","volume":"8","author":"Chaib","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"2025100308202000000_10.9.e004710.36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.mod.2012.09.005","article-title":"Maternal PAK4 expression is required for primitive myelopoiesis in zebrafish","volume":"130","author":"Law","year":"2013","journal-title":"Mech Dev"},{"key":"2025100308202000000_10.9.e004710.37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-380113"},{"key":"2025100308202000000_10.9.e004710.38","first-page":"3395","article-title":"Effect of the chimeric soluble granulocyte colony-stimulating factor receptor on the proliferation of leukemic blast cells from patients with acute myeloblastic leukemia","volume":"57","author":"Asano","year":"1997","journal-title":"Cancer Res"},{"key":"2025100308202000000_10.9.e004710.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.02.035"},{"key":"2025100308202000000_10.9.e004710.40","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00262-017-1963-5","article-title":"Mechanisms overseeing myeloid-derived suppressor cell production in neoplastic disease","volume":"66","author":"Netherby","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"2025100308202000000_10.9.e004710.41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02809","article-title":"Understanding and modulating immunity with cell reprogramming","volume":"10","author":"Pires","year":"2019","journal-title":"Front Immunol"},{"key":"2025100308202000000_10.9.e004710.42","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.bbrc.2019.11.155","article-title":"Blockade of myeloid-derived suppressor cell function by valproic acid enhanced anti-PD-L1 tumor immunotherapy","volume":"522","author":"Adeshakin","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"2025100308202000000_10.9.e004710.43","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/cam4.239","article-title":"A role for G-CSF and GM-CSF in nonmyeloid cancers","volume":"3","author":"Aliper","year":"2014","journal-title":"Cancer Med"},{"key":"2025100308202000000_10.9.e004710.44","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.48.1900"},{"key":"2025100308202000000_10.9.e004710.45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1075"},{"key":"2025100308202000000_10.9.e004710.46","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3278"},{"key":"2025100308202000000_10.9.e004710.47","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-4505"},{"key":"2025100308202000000_10.9.e004710.48","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0039"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-004710","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T15:20:30Z","timestamp":1759504830000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-004710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":48,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,23]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1136\/jitc-2022-004710"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-004710","relation":{},"ISSN":["2051-1426"],"issn-type":[{"type":"electronic","value":"2051-1426"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}